Physiological modeling and extrapolation of pharmacokinetic interactions from binary to more complex chemical mixtures.
The available data on binary interactions are yet to be considered within the context of mixture risk assessment because of our inability to predict the effect of a third or a fourth chemical in the mixture on the interacting binary pairs. Physiologically based pharmacokinetic (PBPK) models represent a potentially useful framework for predicting the consequences of interactions in mixtures of increasing complexity. This article highlights the conceptual basis and validity of PBPK models for extrapolating the occurrence and magnitude of interactions from binary to more complex chemical mixtures. The methodology involves the development of PBPK models for all mixture components and interconnecting them at the level of the tissue where the interaction is occurring. Once all component models are interconnected at the binary level, the PBPK framework simulates the kinetics of all mixture components, accounting for the interactions occurring at various levels in more complex mixtures. This aspect was validated by comparing the simulations of a binary interaction-based PBPK model with experimental data on the inhalation kinetics of m-xylene, toluene, ethyl benzene, dichloromethane, and benzene in mixtures of varying composition and complexity. The ability to predict the kinetics of chemicals in complex mixtures by accounting for binary interactions alone within a PBPK model is a significant step toward the development of interaction-based risk assessment for chemical mixtures.
Krishnan
Kannan
K
Universit de Montréal, Montréal, Canada. kannan.krishnan@umonreal.ca
Haddad
Sami
S
Béliveau
Martin
M
Tardif
Robert
R
D000818:Animals; D004347:Drug Interactions; D004785:Environmental Pollutants / Q000009:adverse effects* / Q000493:pharmacokinetics*; D005544:Forecasting; D006801:Humans; D008962:Models, Theoretical; D010599:Pharmacokinetics; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods; D015262:Xenobiotics / Q000009:adverse effects* / Q000493:pharmacokinetics*
D004785:Environmental Pollutants; D015262:Xenobiotics